Press monitoring
IBA Signs Contract with UZ Leuven to Install the First Proton Therapy Center in Belgium
25.3.2016 | Press monitoring
Louvain-la-Neuve, Belgium, March 25, 2016 - IBA (Ion Beam Applications SA), the world's leading provider of proton therapy solutions for the treatment of cancer, announces today that it has signed a contract with the University Hospitals Leuven (UZ Leuven) and Katholieke Universiteit Leuven (KU Leuven) to install Belgium's first proton therapy...
DNA molecules directly interact with each other based on sequence
25.3.2016 | Press monitoring
Proteins play a large role in DNA regulation, but a new study finds that DNA molecules directly interact with one another in a way that's dependent on the sequence of the DNA and epigenetic factors. This could have implications for how DNA is organized in the cell and even how genes are regulated in different cell types, the researchers...
Bio-on and Italeri unite to use Minerv PHA Supertoys in the toys and models of the future
24.3.2016 | Press monitoring
BOLOGNA, 24 March 2016 - Bio-on announces the launch of a new collaboration with Italeri S.p.A. , a production and distribution leader in the modelling sector. Thanks to this agreement, the manufacture of scale models will be done for the first time with the special grade Minerv PHA Supertoys, the new type of bioplastic developed by Bio-on...
Active Biotech plans to develop tasquinimod for the treatment of multiple myeloma
23.3.2016 | Press monitoring
Lund, March 23, 2016 - Active Biotech (Nasdaq Stockholm: ACTI) today announces that a patent application for the treatment of multiple myeloma with the company's compound tasquinimod, together with an international search report, will be public within short on WIPO's (World Intellectual Property Organization) web site www.wipo.int . With this...
Gene editing could provide a cure for HIV
23.3.2016 | Press monitoring
While antiretroviral drugs do a good job of keeping HIV infections under control, scientists are working hard to come up with a full cure for the condition. A team of researchers from the Lewis Katz School of Medicine at Temple University is making real progress in that regard, successfully testing a gene editing system, demonstrating its ability...
Navamedic enters into agreement with Pennine Healthcare as distributor for Sippi® in the UK
22.3.2016 | Press monitoring
Navamedic ASA (OSE: NAVA), the Norwegian Medtech and pharmaceutical products company, announced today that an agreement has been signed with UK-based Pennine Healthcare, a leading distributor and manufacturer of sterile medical devices, for the launch of Sippi® in Great Britain, Ireland and Northern Ireland.
3-D printing could one day help fix damaged cartilage in knees, noses and ears
21.3.2016 | Press monitoring
Athletes, the elderly and others who suffer from injuries and arthritis can lose cartilage and experience a lot of pain. Researchers are now reporting, however, that they have found a way to produce cartilage tissue by 3-D bioprinting an ink containing human cells, and they have successfully tested it in an in vivo mouse model. The development...
Artificial DNA folds into parcels that can survive inside us
18.3.2016 | Press monitoring
This tiny origami has a lasting appeal. Strands of artificial genetic material have been folded into 3D shapes of our own choosing for the first time. These parcels could be used to carry medicinal cargoes inside the body. Naturally occurring nucleic acids like DNA and RNA perform many biological functions, from information storage to catalysing...
Scientists seek key to converting algae to biofuel
16.3.2016 | Press monitoring
University of Florida Institute of Food and Agricultural Sciences researchers may have found a key to converting algae to fuel. The scientists have found what researchers call a "transcription factor," called ROC40. Bala Rathinasabapathi, a UF/IFAS professor of horticultural sciences, likened a transcription factor's role in controlling the...
Photocure announces grant of patents for Cevira®
15.3.2016 | Press monitoring
Oslo, 15 March 2016 - Photocure (OSE: PHO), a specialty pharmaceutical company with focus on photodynamic technologies in cancer and dermatology today announces that a new patent for Cevira has been granted in Europe.
